Evidence map›Paper›PMID 29159711›Full record

ReviewCurrent treatment options in oncology2017

Treatment of Richter's Syndrome.

Adalgisa Condoluci, Davide Rossi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Richter Transformation: Clinical Manifestations, Evaluation, and Management.Journal of the advanced practitioner in oncology · 2022
    Article
  3. Review
  4. Chronic Lymphocytic Leukemia.Cold Spring Harbor perspectives in medicine · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Adalgisa CondoluciDivision of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Davide RossiDivision of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. davide.rossi@eoc.ch.
Institute of Oncology Research · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementBased on the available literature, mostly derived from retrospective or non-randomized phase I or II studies, it is difficult to define an optimized treatment approach for patients developing Richter's syndrome (RS). Early recognition of chronic lymphocytic leukemia (CLL) patients presenting clinical features suspected for a transformation is useful to avoid exposing them to multiple lines of therapy that, being targeted to CLL progression, have poor efficacy against RS. Because of the low specificity (~ 50-60%) of clinical signs of RS (such as rapid and discordant bulky localized lymphadenopathies, elevated LDH levels, emergent physical deterioration, and/or fever in the absence of infection), a

Indexed as

Cell Transformation, NeoplasticDiagnosis, DifferentialDisease ProgressionHodgkin DiseaseHumansLeukemia, Lymphocytic, Chronic, B-CellLymphadenopathyLymphoma, Large B-Cell, DiffuseRituximabRituximabCLLDLBCLHodgkin lymphomaRichter syndromeTransformationTreatment

Identifiers

PMID29159711
OpenAlexW2769197854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.